The administration of anti-CD3 and anti-CD4 antibodies for immunosuppression likely delayed immune priming, facilitating tumor formation. This parallels the virus’s documented ability to evade or modulate host immune responses during infection, contributing to HPV persistence and pathogenesis [74–78]. This evidence concerns the gene CD4 and infection.